Overview

The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD

Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
To determine if the NMDA antagonist, CP-101,606, is effective for depression
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Antidepressive Agents